← All trials
NCT06653569
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2024
- Primary completion
- Apr 30, 2027
- Completion date
- Sep 30, 2027
- First posted
- Oct 22, 2024
- Last posted
- Nov 12, 2024
- Enrollment
- 484
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of GenevaLead sponsor
- University of GenevaSponsor investigator
- Swiss National Science FoundationCollaborator
- University of ZurichCollaborator
- University of GenevaOfficial
- University of GenevaCollaborator
- University of GenevaCollaborator
- Ente Ospedaliero CantonaleCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.